胰高血糖素样肽-2
翻译科学
短肠综合征
转化医学
相关性(法律)
医学
生物信息学
计算生物学
生物
数据科学
计算机科学
内科学
政治学
病理
生物化学
肽
法学
肠外营养
作者
Daniel J. Drucker,Joel F. Habener,Jens J. Holst
摘要
The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provide perspectives on the historical events and key experimental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone. Important attributes of GLP-1 action and enteroendocrine science are reviewed, with emphasis on mechanistic advances and clinical proof-of-concept studies. The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed. Finally, we summarize recent progress in GLP biology, highlighting emerging concepts and scientific insights with translational relevance.
科研通智能强力驱动
Strongly Powered by AbleSci AI